Market news
Headlines, company news and fresh SEC filings, updated every morning. Stocks we cover show their Quant Score and today’s move — tap one to see the full picture.
Updated daily
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cantor Fitzgerald Investment Advisors L.P. lowered its position in shares of AbbVie Inc. (NYSE: ABBV) by 50.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,450 shares of the company's stock after selling 2,450 shares during the quarter.
AMF Tjanstepension AB cut its position in AbbVie Inc. (NYSE: ABBV) by 22.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,119 shares of the company's stock after selling 6,790 shares during the quarter. AMF Tjanstepension
Both companies pay relatively high-yield dividends. One marries this with growing fundamentals, while the other is basically in reset mode.
AbbVie posted strong Phase 2a results for a potential successor to Skyrizi in Crohn's disease. The company also has a promising eczema candidate that could cement its position in immunology.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidra
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).
Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding behind familiar, trusted names.
Capstone Capital Management Ltd bought a new stake in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,772 shares of the company's stock, valued at approximately $987,000. Several other hedge funds have also bought and sold shares of
Axxcess Wealth Management LLC decreased its holdings in AbbVie Inc. (NYSE: ABBV) by 45.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,309 shares of the company's stock after selling 39,607 shares during the period. Axxcess Wealth Management LLC's holdings in
The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.
AbbVie currently looks stronger on revenue by consistently generating higher overall totals and demonstrating a faster growth trajectory across the measured periods. Both companies record quarter-over-quarter declines at the start of the year, but they maintain generally upward trajectories over the last eight quarters, with AbbVie showing wider increases.
Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very different industries.
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™ IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.
Focused Alpha LLC increased its holdings in AbbVie Inc. (NYSE: ABBV) by 109.0% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,657 shares of the company's stock after purchasing an additional 2,429 shares during the period. Focused Alpha LLC's holdings in AbbVie were
AbbVie generates massive free cash flow while successfully navigating the loss of exclusivity for its top-selling drug. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into gene editing and pain management.
This pharma leader has a history of outperforming during rising interest rates.
Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide affected by autoimmune diseases 1,2 AbbVie Race to Innovate will launch at the 2026 Formula 1 United States Grand Prix in Austin and expand throughout the 2027 season NORTH CHICAGO, Ill., Oct. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team.
Novem Group lessened its holdings in AbbVie Inc. (NYSE: ABBV) by 39.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,356 shares of the company's stock after selling 3,428 shares during the quarter. Novem Group's holdings in AbbVie
Greg Jennings LLC acquired a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 27,954 shares of the company's stock, valued at approximately $7,313,000. AbbVie makes up 4.9% of Greg Jennings LLC's portfolio, making the stock
Rose's Income Garden portfolio review highlights 15 most undervalued and 15 most overvalued dividend stocks using 52-week high/low analysis. Energy names like XOM, SHEL, and CVX have rotated into overvalued territory, while high-yield REITs such as VICI remain top undervalued picks. Dividend yield remains a key selection criterion, with several undervalued stocks offering yields above 5% and investment-grade credit ratings.
ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.
First Bank and Trust cut its holdings in AbbVie Inc. (NYSE: ABBV) by 8.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,959 shares of the company's stock after selling 1,794 shares during the period. AbbVie accounts for 0.7%
IFP Advisors Inc boosted its position in AbbVie Inc. (NYSE: ABBV) by 3.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,869 shares of the company's stock after buying an additional 1,939 shares during the period. IFP
Buffett has warned about "gambling" in the market.
ABBV-0.9%55/100AbbVie Inc.Material event · accepted 9d ago
ABBV-0.9%55/100AbbVie Inc.Material event · accepted 19d ago
Source: Financial Modeling Prep · SEC EDGAR · filings from the last 12 months
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 22d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 22d ago
ABBV-0.9%55/100AbbVie Inc.Material event · accepted 51d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 67d ago
ABBV-0.9%55/100AbbVie Inc.Material event · accepted 67d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 79d ago
ABBV-0.9%55/100AbbVie Inc.Material event · accepted 80d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 80d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 81d ago
ABBV-0.9%55/100AbbVie Inc.Financial report · accepted 82d ago
